Budget impact analysis of acalabrutinib plus venetoclax in chronic lymphocytic leukemia
Objective: To evaluate the budget impact of a fixed-duration combination (FC) “acalabrutinib + venetoclax” regimen for treatmentnaive adults with chronic lymphocytic leukemia (CLL), unmutated IGHV, and absence of del(17p) or mutations in TP53 in the Russian Federation.Material and methods. A determi...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Russo |
| Baskı/Yayın Bilgisi: |
IRBIS LLC
2026-05-01
|
| Seri Bilgileri: | Фармакоэкономика |
| Konular: | |
| Online Erişim: | https://www.pharmacoeconomics.ru/jour/article/view/1375 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|